Research programme: collagen formation inhibitors - FibroGen
Latest Information Update: 23 Mar 2007
At a glance
- Originator FibroGen
- Class Small molecules
- Mechanism of Action Bone morphogenetic protein receptor antagonists; Collagen inhibitors; Mixed function oxygenase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Fibrosis
Most Recent Events
- 15 Aug 2002 This programme is still in active development
- 10 Sep 1999 Preclinical development for Fibrosis in USA (unspecified route)